← ANALYST RATINGS · TIPRANKS
Beam Therapeutics (BEAM): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $58.67, the highest $80.00, the lowest $35.00. The average is +150.0% from the last price of $23.47.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $80.00 | Buy | +240.9% | Reiterated | 15.10.26on TipRanks 06:30 | +4.3%next day −4.0% | ↗ |
| Unknown Analyst | Wedbush | $65.00 | Buy | +176.9% | Reiterated | 14.10.26on TipRanks Oct 15 06:30 | −2.1%next day +4.3% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $78.00 | Buy | +232.3% | Reiterated | 14.10.26on TipRanks 07:11 | −2.1%next day +4.3% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $68.00 | Buy | +189.7% | Reiterated | 13.10.26on TipRanks Oct 14 06:06 | −2.8%next day −2.1% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $70.00 | Buy | +198.3% | Reiterated | 02.10.26on TipRanks Oct 8 07:00 | −0.3%next day +4.1% · 5 days +3.7% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $65.00 | Buy | +176.9% | Reiterated | 09.09.26on TipRanks Sep 16 21:02 | −5.7%next day −2.6% · 5 days −7.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $26.00 | Hold | +10.8% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 → $27.00+3.8% | Hold | +15.0% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $24.50 → $25.00+2.0% | Sell | +6.5% | Reiterated | 09.09.26on TipRanks 09:06 | — | |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $35.00 | Buy | +49.1% | Reiterated | 09.09.26on TipRanks 08:10 | −5.7%next day −2.6% · 5 days −7.1% | ↗ |
| Mara Goldstein★★★★★★★★★★#12071 · hits 34% · avg −5.0% | Mizuho Securities | $37.00 | Buy | +57.6% | Reiterated | 09.09.26on TipRanks 07:30 | −5.7%next day −2.6% · 5 days −7.1% | ↗ |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $26.00 | Hold | +10.8% | Reiterated | 09.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 | Hold | +10.8% | Reiterated | 09.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 | Hold | +10.8% | Reiterated | 09.09.26on TipRanks 06:05 | — | |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $43.00 | Buy | +83.2% | Reiterated | 08.09.26on TipRanks 22:25 | −5.7%next day −2.6% · 5 days −7.1% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 08.09.26on TipRanks 10:55 | −9.0%next day −5.7% · 5 days −12.3% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $44.00 | Buy | +87.5% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | +0.8%next day +0.2% · 5 days −3.9% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $45.00 | Buy | +91.7% | Reiterated | 05.08.26on TipRanks 10:35 | −4.3%next day +0.8% · 5 days −1.7% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $26.00 | Hold | +10.8% | Reiterated | 05.08.26on TipRanks 07:42 | −4.3%next day +0.8% · 5 days −1.7% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $40.00 → $39.00−2.5% | Buy | +66.2% | Assigned | 13.05.26on TipRanks 06:35 | +0.3%next day −8.1% · 5 days −14.7% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $28.00 | Hold | +19.3% | Initiated | 06.01.26on TipRanks Jan 7 08:25 | +5.0%next day +2.4% · 5 days +21.6% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $21.00 | Hold | −10.5% | Reiterated | 05.11.25on TipRanks 03:50 | +1.1%next day +1.4% · 5 days −6.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Beam Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $52.30 at a price of $24.45 (+113.9%); now: $53.73 at $23.47 (+128.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 8 | 8 | 10 | 11 | 13 |
| Buy | 6 | 3 | 3 | 3 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.15 (from $-1.28 to $-1.00). Last quarter: $-1.18.
Sales
Next quarter’s sales estimate — $9M (from $0M to $32M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Beam Therapeutics
- CEO: John Evans
- Employees: 540
- 238 Main Street, Cambridge, MA, 02142, US
- www.beamtx.com
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗